RESuLTS
The success rate of including new oncology drugs in Slovakia was high in [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] . From the 62 oncology drugs registered in this period by the EMA, 48 were included to the Reimbursement List. Before year 2011, innovative oncology drugs were included relatively quickly to reimbursements. This caused a significant growth in expenditures. Expenses on oncology drugs (ATC: L01 and L02) increased in 2003-2011 by 718% (from €15.4 million to €125.7 million) and were €132.7 million in 2013, based on the data of the NHIC (Figure 1 ).
The access to innovative treatments has dramatically changed after the change in legislation. As a consequence of the ICER threshold, there are an increasing number of innovative drugs where the manufacturers don't apply for inclusion in the List of reimbursed drugs (Table 1) . There is a gradual accumulation of new non-reimbursed medicines. If mutual agreement is achieved between the manufacturer and health insurance fund, these drugs can be covered on 'exemptions' . Such agreements usually involve cost-sharing schemes or simple discounts.
In the first year after introduction of the legislative change, the biggest General Health Insurance Fund announced an increase in exemption expenditures by 52% (+€ 4.6 million) in 2012 compared to 2011, while these costs accounted for 2% of the total cost of drugs. Annual growth in 2013 was 33 % (+€ 4.4 million). Overall consumption of oncology drugs covered by all three health insurance funds on exemptions has been increasing at a rate of 66% annually from 2011 ( Figure 3 ).
Prior to 2011, the main factor influencing access to oncology drugs in Slovakia was the way of reimbursement in outpatient care. In 2005, a new system of coverage based on prescription was introduced for expensive oncology drugs. This led to a significant improvement in terms of access and subsequently, oncology drugs consumption increased significantly. This method of reimbursement for oncology drugs was changed back in 2010 to a hospital purchase system, negatively impacting access to oncology drugs. Overall drug expenditures in Slovakia were affected primarily by international price referencing introduced in 2008 and applied twice a year for all reimbursed drugs. The first round of price revision was announced in October 2008 with entry to the List of reimbursed drugs from April 2009. At present, prices in Slovakia are among the lowest in the EU28 as the manufacturer price may not exceed the average of the three lowest prices in EU member states.
In December 2011, a cost/QALY threshold was introduced to legislation, creating a barrier to the inclusion of oncology drugs to the List of reimbursed drugs. There were 20 drugs registered by the EMA in ATC groups L01 and L02 between 07/2011 and 06/2014. Following adoption of this legislation, of the 12 launched drugs (registered by the EMA from 07/2011 in ATC L01 and L02), only 3 oncology drugs were included in the List of reimbursed drugs during 2012-2014 (Table 1) . Uncategorized drugs, i.e. not included in the List of reimbursed drugs, are available only for a limited number of patients by a way of individual exemptions, or by participation in clinical trials.
METHODS
We evaluated the inclusion of oncology drugs, i.e. ATC L01 (Antineoplastic agents) and L02 (Endocrine therapy), to the reimbursement system based on official data from the website of the Ministry of Health SR (MoH). Two periods were compared: before and after introduction of the ICER threshold to the law. We assumed that the new law could influence the submission of drugs that received marketing authorization after 07/2011. The consumption of drugs was analyzed based on the National Health Information Centre (NHIC) database. This database consists of two reports that contain data collected from health insurance funds: 1) consumption of reimbursed drugs on prescriptions and 2) consumption of reimbursed drugs that were administered in outpatient care and paid by health care providers. We decided to choose the NHIC database as it better reflects real consumption in Slovakia compared to IMS Data. Consumption based on IMS data involves a significant portion of the re-export of drugs to other countries (due to low drugs prices in Slovakia). The list of registered oncology drugs was prepared based on information from the EMA website. The quantitative analysis of the inclusion of oncology drugs to the reimbursement system was supplemented by data obtained from a qualitative survey among physicians in order to get a view on the availability of oncology drugs in clinical practice. Four hypotheses were evaluated in the analysis using descriptive statistics and a chi-square test was used for testing the independence of variables.
• Hypothesis H1 -The level of inclusion of new oncology drugs to the List of reimbursed drugs was changed after the introduction of the ICER threshold in the law.
• Hypothesis H2 -After the change of legislation, many manufacturers haven't submitted a reimbursement application for a new cancer drug.
• Hypothesis H3 -The budget impact is an important factor in the decision-making process on inclusion of new products to the List of reimbursed drugs.
• Hypothesis H4 -A negative assessment of the pharmaco-economic analysis is the most common reason for rejecting the inclusion of new oncology drugs to the List of reimbursed drugs. 
CONCLuSION
In Slovakia, the willingness to pay for an additional unit of health defined as a costs/QALY was anchored in legislation. This regulation greatly limited the availability of innovative oncological treatments. The health system in Slovakia needs to introduce efficient and transparent mechanisms that enable the treatment of oncology patients in line with the latest medical findings, while keeping expenses for treatment within economic possibilities.
The analysis of consumption and reimbursement submissions was supplemented by a qualitative survey among physicians focused on access to innovative drugs in clinical practice. Physicians from different regions and specializations were asked to fill in an online questionnaire. The responders (N = 18) named objections to the approval process of non-reimbursed drugs on exemptions. The main objections were: bureaucratic, lengthy and non-transparent environment. Physicians proposed to create a specific financial fund for coverage of costly innovative drugs. They also proposed to evaluate the cost-effectiveness of drugs for severe and rare diseases by a different method than comparing to the strict ICER threshold.
The results of the analysis are summarized in Table 3 . All tested hypotheses were confirmed.
If a reimbursement application is submitted by a manufacturer, the financial indicators still remain the most important parameters in decision-making on drug reimbursement. From the analysis of all manufacturers' submissions from January 2012 (N = 126) we discovered that the budget impact of new drug has a statistically significant impact on the success rate of inclusion to the List of reimbursed drugs (Figure 4 ).
Another important factor in the success of reimbursement application concerns assessment of the pharmaco-economic analysis by the MoH expert working group on pharmaco-economics, clinical outcomes and medical technology assessment. A negative assessment of the pharmaco-economic analysis was the most common reason for a rejection to include a new drug in the reimbursement list in 68% of the total number of failed submissions. The most frequent reason was the wrong selection of type of pharmaco-economic analysis or miscalculation of the QALY. 13% of rejected submissions were justified by a lack of data on efficacy and safety, from which the greatest barrier was a conditional marketing authorization (Table 2 ). 
SOuRCE Of DaTa

Confirmed
The level of inclusion of new oncology drugs to the List of reimbursed drugs changed after the introduction of the ICER threshold in the law. A significantly lower portion of oncology drugs with marketing authorization was included in the List of reimbursed drugs after 2012. After the change of legislation, many manufacturers haven't submitted reimbursement applications for a new cancer drug and we assume that the main reason is achievability of the ICER threshold defined in the law. The budget impact is an important factor in decision-making and there is a significant difference in the success rate of reimbursement submissions with and without budget impact. Negative assessment of pharmaco-economic analysis by health authorities is the most common reason for rejecting the inclusion a new drug to the List of reimbursed drugs. Source: application eRix, Pharm-In, Ltd.
